Sexually Transmitted Infections

Myron S. Cohen, MD

2024 HPTN Regional Meeting
Lima, Perú

HPTN Regional Meeting

1 Dual Prevention Pill

HPTN 104

A multisite, open-label, randomized crossover study comparing adherence to a single daily dual prevention pill (DPP) versus FTC/TDF and Combined Oral Contraception separate pill dosing (2PR), given for pre-exposure prophylaxis and pregnancy prevention in people of childbearing potential

HPTN 104: Study Sites

Sub-Saharan Africa

- Wits RHI Ward 21 CRS
- Eswatini Prevention Center CRS
- Spilhaus CRS
- Makerere University –Johns Hopkins University (MU-JHU) Research Collaboration CRS

2 Broadly neutralizing antibodies

HVTN 206/HPTN 114

- A phase 2 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and neutralization of VRC07-523LS, PGT121.414.LS, and PGDM1400LS broadly neutralizing monoclonal antibodies in adult participants without HIV
- Study to be completed in Brazil, Peru, South Africa and United States – Sites are TBD
- Looks to gain data about neutralization and dosing to inform possible phase 3 Combo AMP trial.

3 HPTN STI Studies

HPTN 113

HPTN Regional Meeting

- A vanguard study to **test a suite of mHealth tools to increase HIV PrEP uptake and adherence** among young Latino/e/x cisgender men and gender nonbinary persons assigned male at birth (AMAB) who have sex with men
- Will also evaluate the uptake, adherence, and acceptability of **doxycycline for STI post-exposure prophylaxis (doxy-PEP)**
- **N** = 400 participants
- **Five sites**: Bronx, UCLA Vine St, Fundacion Huesped, IPEC Fiocruz, San Miguel

ATN 173/HPTN 115 (foXXy doxy)

HPTN Regional Meeting

- Open-label 3-arm RCT investigating use of DoxyPEP for the prevention of STIs (gonorrhea [GC], chlamydia [CT], and early syphilis).
  - Arms (1:1:1): 1) on-demand doxyPEP; 2) weekly doxyPEP; 3) SOC
  - Population: 759 adolescents and youth aged 13-29 assigned female at birth (AFAB) in the US
    - Aim to enroll 20% transgender and gender diverse individuals AFAB
  - 12 sites across the US have been selected (7 ATN and 5 HPTN)
  - Quarterly visits (1 year) + weekly assessments via Health Mpowerment (HMP) app
  - Objectives include efficacy (all incident and individual incident), acceptability, tolerability, self-reported adherence and objective use, and resistance

DMID 24-0020/HPTN 116

- A Phase II trial, open-label, multicenter, non-inferiority, randomized clinical trial to assess the efficacy of doxycycline compared to CDC-recommended IV aqueous penicillin G in the treatment of neurosyphilis and ocular syphilis.
- Approximately 180 participants will be randomized 1:1 to doxycycline or penicillin G across multiple sites in the US and internationally.
- The protocol and site selection process is in development.

HPTN Clinical Research Sites

HPTN Regional Meeting



54
HPTN Sites

13
Countries

21
African Sites

5
Asian Sites

17
North American Sites

11
South American Sites

HPTN Presence in South America

- HPTN 083
- HVTN 704/ HPTN 085 (AMP)
- HPTN 091
- HPTN 113

HPTN Regional Meeting

Thank you

Use this slide to include your headshot, contact information, social media profiles, or to take questions.

Right click photo and select “Change Picture” to replace image.

You may need to select the image and crop using the Picture Format panel in the toolbar.

| @HIVptn

HPTN Regional Meeting

Acknowledgments

Overall support for the HIV Prevention Trials Network (HPTN) is provided by the National Institute of Allergy and Infectious Diseases (NIAID), Office of the Director (OD), National Institutes of Health (NIH), National Institute on Drug Abuse (NIDA), the National Institute of Mental Health (NIMH), and the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD) under Award Numbers UM1AI068619 (HPTN Leadership and Operations Center), UM1AI068617 (HPTN Statistical and Data Management Center), and UM1AI068613 (HPTN Laboratory Center).

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.